Search

The passive layer on Zn Fe Mo coating (7.6 at.% Fe, 1.6 at.% Mo) became damaged in 0.5 M NaCl solution, as shown in ionic current density maps that were observed during 10 h of exposure. The ZnO and Zn(OH) 2 slowly transformed into Zn 5 (OH) 6 (CO 3 ) 2 and Zn 5 (OH) 8 Cl 2 ·H 2 O. At the same time, MoO 2 transformed to MoO 3 and MoO(OH) 2 . The barrier properties of the layer of corrosion products deteriorated so the charge transfer resistance decreased from 13 to 7.4 kΩ cm 2 and the double layer capacitance increased from 4.5 to 62 μF cm –2 after 0.5 h and 10 h exposure, respectively. [ABSTRACT FROM AUTHOR]

Ternary Zn–Fe–Mo alloy coatings, as a potential replacement for zinc coatings, were deposited from a citrate-sulphate solution. It has been shown that by varying the concentration of Na 2 MoO 4 in the plating bath in a range of 0.0025 − 0.05 mol dm −3 it is possible to obtain coatings containing from 0.4 to 2.7% at. Mo and from 2.8 to 7.6% at. Fe. It has been proved that molybdenum and iron do not form intermetallic phases with zinc. However, at higher Mo and Fe content the presence of oxidized molybdenum compounds in the coatings is possible. Among them the most probably are: FeMoO or Mo 5 O 7 (OH) 8 . EIS measurements revealed that the ternary Zn–Fe–Mo alloy (7.6% at. Fe, 2.4% at. Mo) coating offer better corrosion resistance during 24 hours of exposure in NaCl solution than the Zn–Fe (1.7% at.) binary coating and pure Zn coating. The good protective properties of Zn–Fe–Mo coatings are due to the presence of a relatively thin (approx. 7 nm) passive layer enriched in molybdenum oxides and hydroxide compounds. [ABSTRACT FROM AUTHOR]

Ternary Zn–Co–Mo alloy coatings were deposited from a citrate–sulphate bath. In a pH range of 5.5–5.9 the coatings contained 2.3–3.6 wt.% molybdenum and 3.4–3.7 wt.% cobalt. DC and EIS measurements revealed that in the course of 24 h exposure to NaCl solution the corrosion resistance of Zn–Co–Mo alloy coatings was higher than that of Zn and Zn–Co coatings. On the basis of XRD, ALSV and XPS studies it can be stated that the beneficial effect on the corrosion resistance of Zn–Co–Mo coatings has a passive layer composed of: Zn(OH) 2 , ZnO, Mo(IV) oxide and hydroxide and a small amounts of Co 3 O 4 . [ABSTRACT FROM AUTHOR]

There is a need for effective therapy with few side effects for severe acute graft-versus-host disease (GVHD). The placenta protects the fetus from the mother's haploidentical immune system during pregnancy. We report that maternal stromal cells from the fetal membrane, so called decidua stromal cells (DSCs) were more immunosuppressive than other sources of stromal cells. We prospectively treated 21 patients, median 49 years of age (range 1.6-72) for grades II-IV acute GVHD. All had biopsy-proven gastrointestinal GVHD. Majority of patients were either steroid-refractory or had progressive GVHD, 11 patients after >7 days or with progression after 3 days and 10 were refractory to steroid after >3 days. We used an improved protocol where DSCs were thawed and infused in a buffer with 5% human albumin. DSCs were given at a median dose of 1.2 (0.9-2.9) × 106 cells/kg with a median of 2 (1-6) doses, given one week apart. Viability of thawed DSCs was 93% (69-100) and cell passage was 4 (2-4). Complete resolution of GVHD was seen in 11 patients and 10 had a partial response. The cumulative incidence of chronic GVHD was 52%. Six had mild, 4 moderate and 1 severe using the NIH overall chronic GVHD severity scoring. Nine patients died, 3 from relapse, 1 acute GVHD and septicemia, 1 zygomycet infection, 1 liver insufficiency, 1 cerebral hemorrhage, 1 multi-organ failure and 1 chronic GVHD with obstructive bronchiolitis. Four year transplant-related mortality was 28.6% and overall survival was 57%. Survival was similar (p=0.33) compared to all 293 patients that underwent allogeneic hematopoietic cell transplantation during the same period 2012-2015, with a 66 % overall survival. To conclude, DSCs seem to induce a promising long-term outcome for acute GVHD grades II-IV. Randomized trials are under way. [ABSTRACT FROM AUTHOR]